Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2022 | MPN Sessions: Key updates from EHA 2022

Claire Harrison, Jean-Jacques Kiladjian and Ruben Mesa • 12 Jun 2022
EHA 2022
Essential Thrombocythemia Myelofibrosis Myeloproliferative Neoplasms Polycythemia Vera Rare Diseases Danazol Fedratinib Momelotinib Navitoclax Pacritinib Pelabresib Ropeginterferon alfa-2b Ruxolitinib
MOMENTUM SURPASS ET

Welcome to The MPN Sessions brought to you by the Video Journal of Hematological Oncology (VJHemOnc). This exclusive discussion features leading experts Claire Harrison, Ruben Mesa, & Jean-Jacques Kiladjian, who debate key updates in the treatment and management of myeloproliferative neoplasms (MPNs), including myelofibrosis, polycythemia vera, and essential thrombocythemia, following the 27th Congress of the European Hematology Association (EHA) 2022.

More from Claire Harrison

Real-world data on the treatment of adolescents and young adults with MPNs 2:49
Real-world data on the treatment of adolescents and young adults with MPNs
Claire Harrison • 23 Jun 2025
Evolving strategies in MPNs: big data analysis, wearable devices, & targeted therapies 3:20
Evolving strategies in MPNs: big data analysis, wearable devices, & targeted therapies
Claire Harrison • 23 Jun 2025
72-week results from MANIFEST-2: pelabresib plus ruxolitinib in JAK inhibitor-naive myelofibrosis 2:17
72-week results from MANIFEST-2: pelabresib plus ruxolitinib in JAK inhibitor-naive myelofibrosis
Claire Harrison • 23 Jun 2025
The influence of clone size on treatment decisions and disease progression in MPNs 3:01
The influence of clone size on treatment decisions and disease progression in MPNs
Claire Harrison • 23 Jun 2025

More from Jean-Jacques Kiladjian

Preliminary results from trials targeting mutant CALR for the treatment of MPNs 1:16
Preliminary results from trials targeting mutant CALR for the treatment of MPNs
Jean-Jacques Kiladjian • 13 Jun 2025
The disease-modifying potential of CALR-targeted therapies in MPNs 0:55
The disease-modifying potential of CALR-targeted therapies in MPNs
Jean-Jacques Kiladjian • 13 Jun 2025
The management of MPNs in young patients: transitioning from pediatric to adult care 1:57
The management of MPNs in young patients: transitioning from pediatric to adult care
Jean-Jacques Kiladjian • 13 Jun 2025
Defining suboptimal response to ruxolitinib and the strategy for switching treatments 0:53
Defining suboptimal response to ruxolitinib and the strategy for switching treatments
Jean-Jacques Kiladjian • 24 Aug 2024

More from Ruben Mesa

Time without transfusion reliance: quantifying transfusion independence in myelofibrosis 3:11
Time without transfusion reliance: quantifying transfusion independence in myelofibrosis
Ruben Mesa • 23 Aug 2025
The recent shortage of peginterferon alfa-2a and the role of this agent in MPNs 2:12
The recent shortage of peginterferon alfa-2a and the role of this agent in MPNs
Ruben Mesa • 23 Aug 2025
The value and interactive format of the MPN Workshop of the Carolinas 6:05
The value and interactive format of the MPN Workshop of the Carolinas
Naveen Pemmaraju et al. • 22 Aug 2025
The role of non-pharmacological interventions in reducing the symptom burden in MPNs 1:39
The role of non-pharmacological interventions in reducing the symptom burden in MPNs
Ruben Mesa • 23 Aug 2025

Related Videos

Targeting CALR mutations in MPNs: a promising novel immunotherapeutic approach 2:14
Targeting CALR mutations in MPNs: a promising novel immunotherapeutic approach
John Mascarenhas • 4 Sep 2025
Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors 1:19
Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors
John Mascarenhas • 3 Sep 2025
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS 10:06
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS
Asfand Yar Cheema • 5 Sep 2025
The value of fedratinib for the treatment of patients with MF in the second-line setting 1:19
The value of fedratinib for the treatment of patients with MF in the second-line setting
Francesco Passamonti • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals